Diagnostic value of biochemical parameters in the differential diagnosis of an adrenal mass

Annals of the New York Academy of Sciences

Volumn 1073, Issue , 2006, Pages 348-357

  Petersenn, Stephan ^a   Unger, Nicole ^a   Walz, Martin K ^b   Mann, Klaus ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Adrenal mass; Hypercortisolism; Hypertension; Metanephrines; Pheochromocytoma; Primary hyperaldosteronism; Renin

Indexed keywords

ADRENALIN; ALDOSTERONE; CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; METADRENALIN; RENIN;

ADRENAL CORTEX ADENOMA; ADRENAL TUMOR; ALDOSTERONE BLOOD LEVEL; BIOCHEMISTRY; CIRCADIAN RHYTHM; CLINICAL EXAMINATION; CONFERENCE PAPER; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PHEOCHROMOCYTOMA; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; RADIOIMMUNOASSAY; SALIVA ANALYSIS;

EID: 33845506256     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1353.039     Document Type: Conference Paper

References (39)

1. EISENHOFER, G. et al. 2000. Plasma metanephrines: a novel and cost-effective test for pheochromocytoma. Braz. J. Med. Biol. Res. 33: 1157-1169.
2. EISENHOFER, G. 2003. Editorial: biochemical diagnosis of pheochromocytoma - is it time to switch to plasma-free metanephrines?. J. Clin. Endocrinol. Metab. 88: 550-552.
3. RODEN, M. 2002. How to detect pheochromocytomas? - the diagnostic relevance of plasma free metanephrines. Wien. Klin. Wochenschr. 114: 246-251.
4. SAWKA, A.M. et al. 2004. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr. Disord. 4: 2-11.
5. LENDERS, J.W. et al. 1995. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann. Intern. Med. 123: 101-109.
6. SAWKA, A.M. et al. 2003. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J. Clin. Endocrinol. Metab. 88: 553-558.
7. UNGER, N. et al. 2006. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur. J. Endocrinol. 154: 409-417.
8. RABER, W. et al. 2000. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch. Intern. Med. 160: 2957-2963.
9. EISENHOFER, G. et al. 1998. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J. Clin. Endocrinol. Metab. 83: 2175-2185.
10. EISENHOFER, G. 2001. Free or total metanephrines for diagnosis of pheochromocytoma: what is the difference? Clin. Chem. 47: 988-989.
11. EISENHOFER, G. et al. 2001. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev. Endocr. Metab. Disord. 2: 297-311.
12. LENDERS, J.W. et al. 2002. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287: 1427-1434.
13. EISENHOFER, G. et al. 2003. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J. Clin. Endocrinol. Metab. 88: 2656-2666.
14. GARDET, V. et al. 2001. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J. Hypertens. 19: 1029-1035.
15. HIRAMATSU, K. et al. 1981. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med. 141: 1589-1593.
16. GALLAY, B.J. et al. 2001. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am. J. Kidney Dis. 37: 699-705.
17. LOH, K.C. et al. 2000. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J. Clin. Endocrinol. Metab. 85: 2854-2859.
18. FISHMAN, L.M. et al. 1968. Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA 205: 497-502.
19. DISTLER, A. et al. 1977. Low renin hypertension. Contrib. Nephrol. 8: 69-80.
20. MCKENNA, T.J. et al. 1991. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J. Clin. Endocrinol. Metab. 73: 952-957.
21. GRUMBACH, M.M. et al. 2003. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann. Intern. Med. 138: 424-429.
22. TANABE, A. et al. 2003. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J. Clin. Endocrinol. Metab. 88: 2489-2494.
23. ARNAL, J.F. et al. 1991. Recent advances in the investigation of the renin-angiotensin and cardiac natriuretic systems in patients with chronic heart insufficiency. Arch. Mal. Coeur Vaiss. 84: 1273-1280.
24. PLOUIN, P.F. et al. 1990. Immunoradiometric assay of active renin versus determination of plasma renin activity in the clinical investigation of hypertension, congestive heart failure, and liver cirrhosis. Horm. Res. 34: 138-141.
25. GORDON, D.B., I.N. SACHIN & V.N. DODD. 1976. Heterogeneity of renin substrate in human plasma: effect of pregnancy and oral contraceptives. Proc. Soc. Exp. Biol. Med. 153: 314-318.
26. DERKX, F.H. et al. 1986. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J. Clin. Endocrinol. Metab. 63: 1008-1015.
27. SIMON, D. et al. 1992. Two-site direct immunoassay specific for active renin. Clin Chem. 38: 1959-62.
28. UNGER, N. et al. 2004. Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. Eur. J. Endocrinol. 150: 517-523.
29. TRENKEL, S. et al. 2002. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp. Clin. Endocrinol. Diabetes 110: 80-85.
30. SEIFARTH, C. et al. 2002. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin. Endocrinol (Oxf). 57: 457-465.
31. NEWELL-PRICE, J. et al. 1998. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr. Rev. 19: 647-672.
32. ARNALDI, G. et al. 2003. Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88: 5593-5602.
33. MENGDEN, T. et al. 1992. Urinary free cortisol versus 17-hydroxycorticosteroids: a comparative study of their diagnostic value in Cushing's syndrome. Clin. Investig. 70: 545-548.
34. CRAPO, L. 1979. Cushing's syndrome: a review of diagnostic tests. Metabolism 28: 955-977.
35. WOOD, P.J. et al. 1997. Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome - recommendations for a protocol for biochemistry laboratories. Ann. Clin. Biochem. 34: 222-229.
36. NEWELL-PRICE, J. et al. 1995. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin. Endocrinol (Oxf). 43: 545-550.
37. PAPANICOLAOU, D.A. et al. 2002. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J. Clin. Endocrinol. Metab. 87: 4515-4521.
38. RAFF, H., J.L. RAFF & J.W. FINDLING. 1998. Late-night salivary cortisol as a screening test for Cushing's syndrome. J. Clin. Endocrinol. Metab. 83: 2681-2686.
39. TRILCK, M. et al. 2005. Salivary cortisol measurement - a reliable method for the diagnosis of Cushing's syndrome. Exp. Clin. Endocrinol. Diabetes 113: 225-230.